Vaccines

With the holidays upon us, concern continue to increase about the combination of influenza and COVID-19.

New COVID-19 coronavirus vaccine candidates from Johnson & Johnson and Novavax have shown high efficacy on some variants of the disease.

A survey found more Americans looking to get vaccinated as soon as possible versus in December.

The drug maker says their vaccine is still effective against emerging COVID-19 variants, but it still wants to test.

The survey showed that a vast majority of independent practices actively seeking COVID-19 vaccines haven’t received any doses.

The AAFP president says family physicians are uniquely positioned to educate patients, prioritize access, and coordinate administration of COVID-19 coronavirus vaccines.

Let us know how the vaccine rollout is going.

The nearly $20 million in CARES Act funds will be used to expand information sharing between health information exchanges and immunization information systems.

The organization says that cutting primary care practices out of the vaccination process would jeopardize the success of the enterprise.

The organization says it is supportive and encouraged by the incoming administrations plans to address the COVID-19 coronavirus pandemic.

In a statement, ACP President Jacqueline W. Fincher, MD, MACP, says vaccine prioritization should be based on medical need.

The recommendations address the role of physicians as vaccinators.

The Trump administration reversed course saying that the administration of vaccines has been “too narrowly focused.”

The open letter to the HHS secretary urges him to be more transparent about the vaccine rollout.

Top reasons cited to refuse the shots include questions of safety and effectiveness.

After an official floated the idea of only giving patients a partial dose of Moderna’s vaccine, the FDA stepped in to clarify.

Update: Physician organizations are speaking out against the issue.

The drug maker revised its lower estimate for global production by 100 million doses.

Moderna‘s vaccine showed 94.1 percent efficacy in patients 16 and older.

A regulatory panel has given the vaccine approval leaving only the official EUA approval before distribution.

The organizations also thanks healthcare professionals for their work throughout the pandemic.

A survey has found an increase in the share of the general public willing to receive a COVID-19 vaccine.

The organization supports recommendations for the Pfizer BioNTech vaccine.

The vaccine is expected to be authorized for emergency use later this week.

The authorization came late Friday night.

The Vaccines and Related Biological Products Advisory Committee approved the vaccine, BNT162b2, paving the way to emergency use authorization.

The report came out as the U.K. has started vaccinating patients.

As National Influenza Vaccination Week approaches, it’s time for all adults to get a flu shot.

The UK leapfrogged the rest of the western world in accepting the candidate which is shown to be about 95 percent effective against COVID-19.